1,722,646 research outputs found
What rationale for treatment of occupational interstitial lung diseases with the drugs approved for idiopathic pulmonary fibrosis?
No full textPurpose of review To critically discuss the rationale for the use of drugs approved for idiopathic pulmonary fibrosis (IPF) to treat occupational interstitial lung diseases (OILDs). Recent findings Although IPF and OILDs share several clinical, radiological and probably pathogenetic features, currently, OILDs do not have a standard of care. In recent years, our knowledge and understanding of ILDs has improved substantially. Recently, the progressive pulmonary fibrosis (PPF) phenotype, which refers to non-IPF fibrotic ILDs that progress despite appropriate treatment, has been defined. OILDs may also be progressive. Nintedanib, initially approved for treatment of IPF, is also approved in patients with PPF. On the other hand, pirfenidone is approved in IPF but not in PPF, due to the lack of robust evidence of efficacy in this patient subset. Summary OILDs are a large and highly heterogeneous group of conditions without a proper standard of care. Nintedanib may slow functional decline and disease progression in progressive OILDs, and new clinical trials are ongoing
Reasonable length of pre-trial detention: rigid or flexible time limits? A study on Italy from a European perspective
No full textIl saggio analizza il tema della ragionevole durata della detenzione preventiva. In particolare, vengono posti a confronto il sistema convenzionale, che ha natura flessibile, e quello italiano, fondato sull'individuazione di termini rigidi di durata massima della custodia. L'obiettivo del lavoro è quello di dimostrare come né l'uno, né l'altro dei modelli indicati siano di per sé convincenti e come sia necessario pertanto costruire un sistema misto
Reasonable length of pre-trial detention: rigid or flexible time limits? A study on Italy from a European perspective
No full textIl saggio analizza il tema della ragionevole durata della detenzione preventiva. In particolare, vengono posti a confronto il sistema convenzionale, che ha natura flessibile, e quello italiano, fondato sull'individuazione di termini rigidi di durata massima della custodia. L'obiettivo del lavoro è quello di dimostrare come né l'uno, né l'altro dei modelli indicati siano di per sé convincenti e come sia necessario pertanto costruire un sistema misto
More evidence that sarcoidosis is a host disease, and the identity of the aetiological triggers is irrelevant
No full text
Targeting Autotaxin and Lysophosphatidic Acid in Pulmonary Fibrosis Admilparant’s Positive Results Show Continued Promise
No full textThe future of clinical trials in idiopathic pulmonary fibrosis
Full text linkPurpose of reviewIdiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis and limited therapeutic options. A multitude of promising compounds are currently being investigated; however, the design and conductance of late-phase clinical trials in IPF has proven particularly challenging.Recent findingsDespite promising phase 2 data, ziritaxestat, an autotaxin inhibitor, pentraxin-2, an endogenous protein that regulates wound healing and fibrosis, and pamrevlumab, a human monoclonal antibody against connective tissue growth factor, failed to show efficacy in phase 3 trials. Endpoint selection is critical for the design, execution, and success of clinical trials; recently, attention has been paid to the assessment of how patients feel, function, and survive with the aim of aligning scientific objectives and patient needs in IPF. External control arms are control patients that derive from historical randomized controlled trials, registries, or electronic health records. They are increasingly used to assess treatment efficacy in clinical trials owing to their potential to reduce study duration and cost and increase generalizability of findings.SummaryAdvances in study design, end point selection and statistical analysis, and innovative strategies for more efficient enrolment of study participants have the potential to increase the likelihood of success of late-phase clinical trials in IPF
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
